Meliglix

Sitagliptin, the active ingredient in Meliglix, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adults, helping to improve blood glucose control when used with diet and exercise.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times and comprehensive technical support.

Sitagliptin, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Adjunct to diet and exercise: enhances glycemic control when combined with lifestyle measures. Combination therapy: can be co‑prescribed with metformin or other antidiabetic agents to improve overall glucose management.

Sitagliptin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nasopharyngitis - Headache - Nausea

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Acute kidney injury in susceptible patients

When prescribing sitagliptin, clinicians should consider several safety aspects.

Renal function: assess baseline and monitor periodically, dose may need adjustment in renal impairment. Hypoglycemia risk: caution when used with insulin or sulfonylureas, monitor blood glucose closely. Pancreatitis: discontinue if patient develops persistent abdominal pain, nausea, or vomiting. Hypersensitivity: discontinue at first sign of rash, angioedema, or severe skin reactions. Pregnancy and lactation: use only if potential benefit justifies potential risk; consult healthcare provider. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Sitagliptin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycemia. - Strong diuretics (e.g., furosemide): may reduce renal clearance of sitagliptin, raising exposure. - CYP2C8 inhibitors (e.g., gemfibrozil): can increase sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may lower sitagliptin concentrations. - ACE inhibitors: additive effect on blood pressure may occur. - Warfarin: monitor INR as sitagliptin may affect anticoagulation control.